This is an aggregated industry headline. Read the full story at FierceBiotech →
F2G, Shionogi prep regulatory push after novel antifungal passes ph. 3 test
F2G and Shionogi have released phase 3 data for the oral antifungal drug olorofim, demonstrating its non-inferiority compared with an existing drug for invasive aspergillosis.
By FierceBiotech
· Jun 18, 2026
· via FierceBiotech
Image: FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Four years after Spero Therapeutics received a complete response letter from the FDA, rejecting its oral treat…
The WeekBriefing
Regulators appear receptive to Moderna's flu vaccine, UniQure prepares a Huntington's filing, and Lilly announ…
The WeekSTAT News ↗
A wide gap exists between what Patrick Soon-Shiong says his cancer drugs can achieve and what they actually do…